AXIM Biotechnologies, Inc. (AXIM)
USD 0.0
(17.65%)
USD 0.0
(17.65%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -2.75 Million USD | 40.88% |
| 2022 | -4.65 Million USD | 41.73% |
| 2021 | -7.98 Million USD | -61.35% |
| 2020 | -4.94 Million USD | 23.93% |
| 2019 | -6.5 Million USD | -29.18% |
| 2018 | -5.03 Million USD | -59.92% |
| 2017 | -3.14 Million USD | 16.24% |
| 2016 | -3.75 Million USD | 62.59% |
| 2015 | -10.04 Million USD | -1887.14% |
| 2014 | -505.72 Thousand USD | -466.84% |
| 2013 | -89.21 Thousand USD | -498.62% |
| 2012 | -14.9 Thousand USD | -433.43% |
| 2011 | -2794.00 USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -569.44 Thousand USD | -40.83% |
| 2024 Q1 | -404.36 Thousand USD | 46.37% |
| 2023 FY | -2.75 Million USD | 40.88% |
| 2023 Q3 | -588.53 Thousand USD | 15.65% |
| 2023 Q4 | -753.94 Thousand USD | -28.1% |
| 2023 Q1 | -710.63 Thousand USD | 37.79% |
| 2023 Q2 | -697.72 Thousand USD | 1.82% |
| 2022 FY | -4.65 Million USD | 41.73% |
| 2022 Q2 | -1.05 Million USD | 6.45% |
| 2022 Q4 | -1.14 Million USD | 13.32% |
| 2022 Q1 | -1.13 Million USD | 85.77% |
| 2022 Q3 | -1.31 Million USD | -24.34% |
| 2021 Q3 | -3.27 Million USD | -50.32% |
| 2021 FY | -7.98 Million USD | -61.35% |
| 2021 Q1 | -868 Thousand USD | 61.6% |
| 2021 Q2 | -2.18 Million USD | -151.27% |
| 2021 Q4 | -7.95 Million USD | -142.79% |
| 2020 Q1 | -1.84 Million USD | -47.4% |
| 2020 Q4 | -2.26 Million USD | -74.06% |
| 2020 Q3 | -1.29 Million USD | -95.93% |
| 2020 FY | -4.94 Million USD | 23.93% |
| 2020 Q2 | -662.86 Thousand USD | 64.12% |
| 2019 Q1 | -2.29 Million USD | -217.19% |
| 2019 FY | -6.5 Million USD | -29.18% |
| 2019 Q4 | -1.25 Million USD | -12.47% |
| 2019 Q3 | -1.11 Million USD | 39.55% |
| 2019 Q2 | -1.84 Million USD | 19.61% |
| 2018 Q2 | -1.34 Million USD | 34.14% |
| 2018 Q1 | -2.03 Million USD | -93.84% |
| 2018 FY | -5.03 Million USD | -59.92% |
| 2018 Q4 | -723.11 Thousand USD | 22.73% |
| 2018 Q3 | -935.82 Thousand USD | 30.21% |
| 2017 Q2 | -437.24 Thousand USD | 8.2% |
| 2017 Q1 | -476.32 Thousand USD | 38.16% |
| 2017 FY | -3.14 Million USD | 16.24% |
| 2017 Q4 | -1.05 Million USD | 11.36% |
| 2017 Q3 | -1.18 Million USD | -171.02% |
| 2016 Q2 | -491.48 Thousand USD | 47.84% |
| 2016 Q4 | -770.22 Thousand USD | 50.49% |
| 2016 Q1 | -942.18 Thousand USD | 85.07% |
| 2016 FY | -3.75 Million USD | 62.59% |
| 2016 Q3 | -1.55 Million USD | -216.5% |
| 2015 Q3 | -1.69 Million USD | -8.38% |
| 2015 Q2 | -1.56 Million USD | -219.24% |
| 2015 FY | -10.04 Million USD | -1887.14% |
| 2015 Q1 | -488.81 Thousand USD | -50.22% |
| 2015 Q4 | -6.3 Million USD | -273.03% |
| 2014 Q2 | -44.76 Thousand USD | -487.39% |
| 2014 FY | -505.72 Thousand USD | -466.84% |
| 2014 Q4 | -325.4 Thousand USD | -154.33% |
| 2014 Q3 | -127.94 Thousand USD | -185.81% |
| 2014 Q1 | -7621.00 USD | 82.26% |
| 2013 Q4 | -42.96 Thousand USD | -22713.16% |
| 2013 Q2 | -29.79 Thousand USD | -412.19% |
| 2013 Q1 | -5817.00 USD | 60.92% |
| 2013 FY | -89.21 Thousand USD | -498.62% |
| 2013 Q3 | 190.00 USD | 100.64% |
| 2012 Q1 | -510.00 USD | -141.87% |
| 2012 Q3 | 2400.00 USD | 1095.85% |
| 2012 Q2 | -241.00 USD | 52.75% |
| 2012 FY | -14.9 Thousand USD | -433.43% |
| 2012 Q4 | -14.88 Thousand USD | -720.25% |
| 2011 Q4 | 1218.00 USD | 130.36% |
| 2011 FY | -2794.00 USD | 0.0% |
| 2011 Q2 | - USD | 0.0% |
| 2011 Q1 | - USD | 0.0% |
| 2011 Q3 | -4012.00 USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | -1.33 Million USD | -105.989% |
| Arch Therapeutics, Inc. | -5.04 Million USD | 45.468% |
| Evofem Biosciences, Inc. | -17.84 Million USD | 84.587% |
| Nascent Biotech, Inc. | -2.22 Million USD | -23.363% |
| Rebus Holdings, Inc. | -664 Thousand USD | -314.283% |
| Santhera Pharmaceuticals Holding AG | 81.85 Million USD | 103.361% |
| Qrons Inc. | -643.67 Thousand USD | -327.363% |
| Adynxx, Inc. | - USD | Infinity% |
| Neon Bloom, Inc. | -389.57 Thousand USD | -606.122% |
| Northwest Biotherapeutics, Inc. | -55.5 Million USD | 95.044% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | -562.089% |
| Skye Bioscience, Inc. | -13.67 Million USD | 79.879% |
| Eiger BioPharmaceuticals, Inc. | -71.78 Million USD | 96.168% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | 155.97% |
| Institute of Biomedical Research Corp. | -261.72 Thousand USD | -951.038% |
| SQZ Biotechnologies Company | -75.82 Million USD | 96.372% |
| Intellipharmaceutics International Inc. | -2.85 Million USD | 3.497% |
| Propanc Biopharma, Inc. | -1.53 Million USD | -79.085% |
| Mesoblast Limited | -84.14 Million USD | 96.731% |
| Marizyme, Inc. | -34.08 Million USD | 91.93% |
| Genus plc | 6.4 Million USD | 142.982% |
| VioQuest Pharmaceuticals, Inc. | 9.74 Million USD | 128.236% |
| Pharming Group N.V. | -4.87 Million USD | 43.625% |
| Therapeutic Solutions International, Inc. | -1.98 Million USD | -38.478% |
| CNBX Pharmaceuticals Inc. | -931.38 Thousand USD | -195.351% |
| Nymox Pharmaceutical Corporation | -8.35 Million USD | 67.056% |
| ContraFect Corporation | -56.88 Million USD | 95.165% |
| PsyBio Therapeutics Corp. | -4.55 Million USD | 39.605% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | -96.209% |
| IMV Inc. | -38.67 Million USD | 92.887% |
| MultiCell Technologies, Inc. | -722.81 USD | -380475.67% |
| ONE Bio Corp. | 13.68 Million USD | 120.106% |
| Accustem Sciences Inc. | -3.74 Million USD | 26.574% |
| RVL Pharmaceuticals plc | -58.99 Million USD | 95.337% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | -483.06 Thousand USD | -469.459% |
| Q BioMed Inc. | -3.44 Million USD | 20.164% |
| Emmaus Life Sciences, Inc. | 3.54 Million USD | 177.707% |
| Mosaic ImmunoEngineering Inc. | -2.62 Million USD | -4.693% |
| Biomind Labs Inc. | -1 Million USD | -172.467% |
| American Oriental Bioengineering, Inc. | -54.97 Million USD | 94.996% |
| Provectus Biopharmaceuticals, Inc. | -2.9 Million USD | 5.184% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Oncotelic Therapeutics, Inc. | -6.64 Million USD | 58.622% |
| GlobeStar Therapeutics Corporation | -1.86 Million USD | -47.548% |
| THC Farmaceuticals, Inc. | -29.95 Thousand USD | -9084.158% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 82.666% |
| Curative Biotechnology, Inc. | -1.93 Million USD | -42.338% |
| GB Sciences, Inc. | -1.42 Million USD | -93.652% |
| Alpha Cognition Inc. | -9.7 Million USD | 71.657% |
| HST Global, Inc. | -140.9 Thousand USD | -1852.237% |
| CSL Limited | 3.7 Billion USD | 100.074% |
| Wesana Health Holdings Inc. | -1.12 Million USD | -144.539% |
| Halberd Corporation | -75.05 Thousand USD | -3565.342% |
| Enzolytics Inc. | -2.14 Million USD | -28.017% |
| Agentix Corp. | -1.37 Million USD | -100.534% |
| Resverlogix Corp. | -12.74 Million USD | 78.423% |
| Nuo Therapeutics, Inc. | -3.16 Million USD | 13.175% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -425.04 Million USD | 99.353% |
| Enzon Pharmaceuticals, Inc. | -1.04 Million USD | -163.49% |
| Endonovo Therapeutics, Inc. | -2.91 Million USD | 5.775% |
| RespireRx Pharmaceuticals Inc. | -1.57 Million USD | -74.175% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -3.4 Million USD | 19.211% |
| AVAX Technologies, Inc. | 6.69 Million USD | 141.101% |
| Zenith Capital Corp. | -8.94 Million USD | 69.24% |
| Genscript Biotech Corporation | -415.79 Million USD | 99.338% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -15690.362% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -2.45 Million USD | -12.036% |
| WPD Pharmaceuticals Inc. | -171.5 Thousand USD | -1503.899% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | -37.216% |
| Kadimastem Ltd | -3.04 Million USD | 9.519% |
| Helix BioMedix, Inc. | -984.05 Thousand USD | -179.542% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -1.25 Million USD | -119.016% |
| BioStem Technologies, Inc. | -7.77 Million USD | 64.637% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -181.48 Thousand USD | -1415.739% |
| LadRx Corporation | -3.82 Million USD | 28.057% |
| Cell Source, Inc. | -4.32 Million USD | 36.402% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | -300.442% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | -300.442% |
| NovAccess Global Inc. | -2.46 Million USD | -11.516% |
| Affymax, Inc. | -15.04 Million USD | 81.717% |
| Itoco Inc. | -919.14 Thousand USD | -199.284% |
| Rasna Therapeutics, Inc. | -4.23 Million USD | 35.097% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | -145.83% |
| Mobile Lads Corp. | -554.55 Thousand USD | -396.049% |
| CytoDyn Inc. | -18.05 Million USD | 84.767% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -25.17 Thousand USD | -10829.039% |
| NanoSphere Health Sciences Inc. | -220.07 Thousand USD | -1149.938% |
| Alseres Pharmaceuticals, Inc. | -564.72 Thousand USD | -387.113% |
| SYBLEU INC | -149.18 Thousand USD | -1743.973% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | -1.81 Million USD | -51.451% |
| International Stem Cell Corporation | -663 Thousand USD | -314.908% |
| Bioxytran, Inc. | -3.82 Million USD | 27.991% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -5125.758% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -20.34 Thousand USD | -13424.282% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -36.26 Million USD | 92.415% |
| Adhera Therapeutics, Inc. | -1.61 Million USD | -70.015% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -735.83 Thousand USD | -273.839% |
| Innovation Pharmaceuticals Inc. | -3.11 Million USD | 11.577% |
| Neutra Corp. | -229.48 Thousand USD | -1098.696% |
| Windtree Therapeutics, Inc. | -17.53 Million USD | 84.316% |
| PureTech Health plc | -146.19 Million USD | 98.118% |
| Coeptis Therapeutics, Inc. | -21.49 Million USD | 87.2% |
| IXICO plc | -1.43 Million USD | -91.429% |
| IntelGenx Technologies Corp. | -9.49 Million USD | 71.016% |
| Gelesis Holdings, Inc. | -121.8 Million USD | 97.742% |
| CSL Limited | 3.81 Billion USD | 100.072% |
| Cellectis S.A. | -108.85 Million USD | 97.473% |